|
|
Blood, 15 August 2008, Vol. 112, No. 4, pp. 1374-1381.
Prepublished online as a Blood First Edition Paper on May 28, 2008; DOI 10.1182/blood-2008-01-136465.
Previous Article | Next Article 
Submitted January 28, 2008
Accepted May 3, 2008
Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials
Wolfram Klapper*, Monika Szczepanowski, Birgit Burkhardt, Hilmar Berger, Maciej Rosolowski, Stefan Bentink, Carsten Schwaenen, Swen Wessendorf, Rainer Spang, Peter Moller, Martin Leo Hansmann, Heinz-Wolfram Bernd, German Ott, Michael Hummel, Harald Stein, Markus Loeffler, Lorenz Trumper, Martin Zimmermann, Alfred Reiter, and Reiner Siebert
Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
Children’s University Hospital, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
Institute of Functional Genomics, University of Regensburg, Regensburg, Germany
Cytogenetic and Molecular Diagnostics, Internal Medicine III, University Hospital of Ulm, Ulm, Germany
Institute of Pathology, University Hospital of Ulm, Ulm, Germany
Institute of Pathology, University of Frankfurt, Frankfurt, Germany
Institute of Pathology, University Hospital Schleswig-Holstein, Campus Lubeck, Lubeck, Germany
Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
Institute of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
Department of Hematology and Oncology, Georg-August University of Gottingen, Gottingen, Germany
Department of Pediatric Hematology and Oncology, University of Hannover, Germany
NHL-BFM Study Center, Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany
Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
* Corresponding author; email: wklapper{at}path.uni-kiel.de.
The spectrum of entities, the therapeutic strategy and the outcome of mature aggressive B-cell Non-Hodgkin lymphomas (maB-NHL) differs between children and adolescents on the one hand and adult patients on the other. Whereas adult maB-NHL have been studied in detail, data on molecular profiling of pediatric maB-NHL are hitherto lacking. We analyzed 65 cases of maB-NHL from patients up to 18 years of age by gene expression profiling, matrix CGH, FISH and immunohistochemistry. The majority of the analyzed pediatric patients were treated within prospective trials (n=49). We compared this group to a series of 182 previously published cases of adult maB-NHL.
Gene expression profiling reclassified 31% of morphologically defined diffuse large B-cell lymphomas as molecular Burkitt lymphoma (mBL). The subgroups obtained by molecular reclassification did not show any difference in outcome in children treated with the NHL-BFM protocols. No differences were detectable between pediatric and adult mBL with regard to gene expression or chromosomal imbalances. This is the first report on molecular profiling of pediatric B-NHL showing mBL to be much more prominent in children than suggested by morphological assessment. Based on molecular profiling mBL is a molecularly homogeneous disease across children and adults.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
U. Bacher, A. Kohlmann, and T. Haferlach
Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies
Brief Funct Genomic Proteomic,
May 27, 2009;
(2009)
elp011v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|